# Hylomorph

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hylomorph

- Industry: Medical Devices & Equipment
- Headquarters: Zurich, Switzerland
- Website: www.hylomorph-medical.com
- Total disclosed funding: $15M
- Latest round: Series B (Sep 5, 2023)
- Investors on record: 9

## About

Based in Switzerland, Hylomorph AG specializes in developing innovative implantable medical devices and drug-device combinations aimed at enhancing patient outcomes by minimizing complications associated with surgical procedures.Hylomorph AG is focused on creating advanced medical solutions. Founded in Zurich, Switzerland in 2014, the company has successfully completed 8 deals with notable funding rounds, including a Series B round on September 5, 2023, which raised CHF 4.5 million led by Efficient Frontier Investing. The CEO of Hylomorph is Simone Bottan.Hylomorph specializes in the development of innovative implantable medical devices and drug-device combinations, designed to enhance patient outcomes and prevent complications. Their core product, Vesta, is an advanced envelope for cardiac implantable electronic devices (CIEDs) that improves biocompatibility and reduces post-surgical complication risks. The company tailors its offerings for healthcare professionals and targets clients in hospitals and clinics, especially in Europe and North America.Hylomorph generates revenue through the direct sales of its medical devices, primarily targeting healthcare institutions such as hospitals and specialized clinics. Their flagship product, Vesta, is positioned as a premium offering, and the revenue streams are supported by partnerships with distributors, enhancing the accessibility of their products to healthcare providers.In September 2023, Hylomorph AG raised CHF 4.5 million in Series B funding, led by Efficient Frontier Investing and supported by multiple investors. This funding will facilitate the expansion of their product offerings and support their move towards commercial sales. The company plans to utilize this capital to develop upcoming products and strategically expand into new markets, focusing on enhancing their presence in Europe and North America.

## Funding rounds

- Series B, Sep 5, 2023, $5M — Zürcher Kantonalbank, Club Degli Investitori, StartAngels Network, Efficient Frontier Investing, Verve Ventures, Excellis, Interconsult srl
- Series B, Dec 3, 2021, $6.6M — Zürcher Kantonalbank, StartAngels Network, Efficient Frontier Investing, Verve Ventures, Geneva Smart Invest
- Series A, Aug 30, 2018, $3.3M — Zürcher Kantonalbank, Fongit Seed Invest, StartAngels Network, Verve Ventures

## Investors

- Zürcher Kantonalbank — Series A, Series B
- Fongit Seed Invest (https://capitalatlas.ai/funds/fongit-seed-invest) — Series A
- StartAngels Network — Series A, Series B
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Series A, Series B
- Efficient Frontier Investing (https://capitalatlas.ai/funds/efficient-frontier-investing) — Series B
- Geneva Smart Invest (https://capitalatlas.ai/funds/geneva-smart-invest) — Series B
- Club Degli Investitori (https://capitalatlas.ai/funds/club-degli-investitori) — Series B
- Excellis (https://capitalatlas.ai/funds/excellis) — Series B
- Interconsult srl — Series B